We're sunsetting PodQuest on 2025-07-28. Thank you for your support!
Export Podcast Subscriptions
cover of episode Ozempic and Wegovy: How 2 diabetes medications became the most popular weight-loss drugs

Ozempic and Wegovy: How 2 diabetes medications became the most popular weight-loss drugs

2023/12/20
logo of podcast Most Innovative Companies

Most Innovative Companies
AI Deep Dive AI Chapters Transcript
People
A
Adam Bluestein
T
Trina Spear
Y
Yasmin Gagne
Topics
Adam Bluestein: Novo Nordisk 公司最初专注于生产胰岛素，但由于市场竞争和价格压力，公司转向研发 GLP-1 激动剂，最终开发出 Ozempic 和 Wegovy 等减肥药。Ozempic 和 Wegovy 的成功源于其在临床试验中展现出的显著减肥效果，以及其便捷的每周一次的注射方式。尽管如此，这些药物也存在一些副作用，例如恶心、呕吐、腹泻等胃肠道问题，以及潜在的精神疾病风险。此外，长期使用这些药物的潜在影响尚不明确，这导致一些保险公司对其覆盖范围有限。美国药品定价机制的复杂性也影响了这些药物的市场价格和可及性。目前，Novo Nordisk 正在进行大量研究，以进一步了解这些药物的作用机制，并探索其在治疗其他疾病方面的潜力，例如心血管疾病和肾脏疾病。 Yasmin Gagne: 节目讨论了 Ozempic 和 Wegovy 的流行，以及其对社会和文化的影响。主持人与嘉宾讨论了这些药物的工作机制、价格、副作用以及对肥胖症的认知。节目中还采访了 Figs 公司的联合创始人 Trina Spear，讨论了该公司如何为医疗保健专业人员提供创新型服装。

Deep Dive

Chapters
The episode discusses the rise of Ozempic and Wegovy, two diabetes medications that have become popular weight-loss drugs in the U.S., and the factors contributing to their popularity.

Shownotes Transcript

In the United States, nearly three-quarters of adults qualify as overweight or obese, 42% of whom are considered obese. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035.

‘Fast Company’ contributing writer Adam Bluestein joined us to break down how Novo Nordisk, the company behind Ozempic and Wegovy, developed and marketed its weight-loss drugs. He also explained why the drugs have become so popular in the U.S., how drug pricing is extremely complicated and . . . how the medications actually work to help people lose weight.

Also, we chatted with Trina Spear about how she founded Figs, a DTC healthcare apparel company.